he said: "our research shows that people, on average, believe that only 34 per cent of protection claims are paid out by insurance companies.
.
.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.